Abraxis BioScience (ABII)

Net Revenue

Net revenue for the year ended December 31, 2009 increased $13.7 million, or 4.0%, to $359.0 million as compared to $345.3 million in 2008. Included in net revenue for the year ended December 2008 was $36.4 million of recognized deferred revenue associated with the co-promotion agreement with AstraZeneca (“Co-Promotion Agreement”), which was terminated effective January 2009.

Abraxane^® revenue for the year ended December 31, 2009 decreased $21.1 million, or 6.3%, to $314.5 million as compared to $335.6 million in 2008, primarily due to the elimination of the recognized deferred revenue related to the Co-Promotion Agreement. Excluding the recognition of the deferred revenue associated with the Co-Promotion Agreement, Abraxane^® revenue for the year ended December 31, 2009 increased $15.2 million to $314.5 million compared to $299.3 million for the same period in 2008. The increase in Abraxane^® revenue was driven by incremental revenue from the global expansion into China, Australia and the European Union and higher average net selling price from sales within the United States. Abraxane^® revenue represented 87.6% of net revenue for the year ended December 31, 2009 as compared to 97.2% in 2008.

Other revenue increased $34.8 million to $44.5 million as compared to $9.7 million for the same period in 2008 due primarily to raw material product sales of $32.5 million, which began in 2009. Revenue from contract manufacturing contributed an additional increase of $2.3 million.

Net revenue for the year ended December 31, 2008 increased $11.6 million, or 3.5%, to $345.3 million as compared to $333.7 million in 2007. Included in net revenue for the year ended December 31, 2008 was $39.5 million of recognized deferred revenue relating to the Co-Promotion Agreement and the license agreements with Taiho and Green Cross as compared to $39.4 million for the year ended December 31, 2007.

Abraxane^® revenue for the year ended December 31, 2008 increased $10.9 million to $335.6 million as compared to $324.7 million in 2007. The increase was primarily the result of a price increase and increased unit sales of Abraxane^®. Excluding the recognition of deferred revenue relating to the Co-Promotion Agreement, total Abraxane^® revenue for the year ended December 31, 2008 increased $10.9 million, or 3.8%, to $299.3 million compared to $288.3 from the prior year. Abraxane^® revenue represented 97.2% of net revenue for the year ended December 31, 2008 as compared to 97.3% in 2007.

Other revenue increased to $9.7 million in 2008 from $9.0 million in 2007, primarily due to higher management fees revenue from our Melrose Park manufacturing and R&D facilities, and service revenue from our Phoenix plant, partially offset by lower licensing revenues due to a milestone payment received in 2007.

Net Revenue

Net revenue for the three months ended March 31, 2009 decreased by $9.5 million, or 11.6% to $72.6 million as compared to $82.1 million for the same period in 2008. Included in net revenue for the three months ended March 31, 2009 was $0.8 million of recognized deferred revenue as compared to $10.2 million in the prior year period.

Abraxane revenue for the three months ended March 31, 2009 decreased $9.3 million to $70.6 million compared to $79.9 million for the same period of 2008. The decrease was primarily due to a decrease in deferred revenue of $9.1 million related to the reacquisition of Abraxane marketing rights in the U.S. effective in January 2009. Excluding the recognition of deferred revenue, total Abraxane revenue for the three months ended March 31, 2009 decreased by $0.2 million, or 0.3%, to $70.6 million as compared to $70.8 million for the previous year’s comparable period.

Net Revenue

Net revenue for the year ended December 31, 2008 increased $11.6 million, or 3.5%, to $345.3 million as compared to $333.7 million in 2007. Included in net revenue for the year ended December 31, 2008 was $39.5 million of recognized deferred revenue relating to the co-promotion agreement with AstraZeneca (“Co-Promotion Agreement”) and the license agreements with Taiho and Green Cross as compared to $39.4 million for the year ended December 31, 2007. The Co-Promotion Agreement was terminated effective January 2009.

Abraxane^® revenue for the year ended December 31, 2008 increased $10.9 million to $335.6 million as compared to $324.7 million in 2007. The increase was primarily the result of a price increase and increased unit sales of Abraxane^®. Excluding the recognition of deferred revenue relating to the Co-Promotion Agreement, total Abraxane^® revenue for the year ended December 31, 2008 increased 3.8% to $299.3 million compared to $288.3 from the prior year. Abraxane^® revenue represented 97.2% of net revenue for the year ended December 31, 2008 as compared to 97.3% in 2007.

Other revenue increased to $9.7 million in 2008 from $9.0 million in 2007, primarily due to higher management fees revenue from our Melrose Park manufacturing and R&D facilities, and service revenue from our Phoenix plant, partially offset by lower licensing revenues due to a milestone payment received in 2007.

Net revenue in 2007 increased $151.4 million, or 83.0%, to $333.7 million as compared to the prior year. Excluding the recognition of deferred revenue relating to the Co-Promotion Agreement, Abraxane^® revenue increased 84.0%, to $288.3 million compared to the prior year. The increase in Abraxane^® sales was primarily due to product sales from increased market penetration. Abraxane^® revenue represented 97.3% of net revenue for the year ended December 31, 2007 as compared to 96.0% in 2006.

Other revenue increased to $9.0 million in 2007 from $7.4 million in 2006, primarily due to $1.3 million of contract manufacturing revenue from the Phoenix manufacturing facility.

Net Revenue

Net revenue for the nine months ended September 30, 2008 increased by $10.2 million, or 4.2%, to $253.1 million as compared to $242.9 million for the same period in 2007. Net revenue for the nine months ended September 30, 2008 included $29.6 million of recognized deferred revenue relating to the AstraZeneca co-promotion agreement and the license agreements with Taiho and Green Cross as compared to $29.4 million of recognized deferred revenue for the same period in the prior year.

Abraxane revenue for the nine months ended September 30, 2008 increased $9.9 million to $245.8 million compared to $235.9 million for the same period in 2007. The increase was primarily due to a price increase and increased unit sales of Abraxane. Excluding the recognition of deferred revenue, total Abraxane revenue for the nine months ended September 30, 2008 increased to $218.5 million, or 4.7%, as compared to $208.6 million for the previous year’s comparable period.

Net Revenue

Net revenue for the six months ended June 30, 2008 increased by $4.7 million, or 3.0%, to $159.8 million as compared to $155.1 million for the same period in 2007. Net revenue for the six months ended June 30, 2008 included $20.4 million of recognized deferred revenue relating to the AstraZeneca co-promotion agreement and the license agreements with Taiho and Green Cross as compared to $19.6 million of recognized deferred revenue for the same period in the prior year.

Abraxane revenue for the six months ended June 30, 2008 increased $4.2 million to $153.8 million compared to $149.6 million for the same period in 2007. The increase was primarily due to a price increase which took effect in January 2008 and slightly higher unit sales of Abraxane in the first quarter of 2008. Excluding the recognition of deferred revenue, total Abraxane revenue for the six months ended June 30, 2008 increased to $135.6 million, or 3.2%, as compared to $131.4 million for the previous year’s comparable period.

Net Revenue

Net revenue for the three months ended March 31, 2008 increased $10.2 million, or 14.3%, to $82.1 million as compared to $71.9 million for the same period in 2007. Included in net revenue for the three months ended March 31, 2008 was $10.2 million of recognized deferred revenue primarily relating to the co-promotion agreement with AstraZeneca and the license agreements with Taiho as compared to $9.8 million in the prior year period.

Abraxane ^® revenue for the three months ended March 31, 2008 increased $9.0 million to $79.9 compared to $70.9 million in the same period of 2007. The increase was primarily due to increased market penetration of Abraxane ^® and a price increase which took effect in January 2008. Excluding the recognition of deferred revenue, total Abraxane ^® revenue for the three months ended March 31, 2008 increased to $70.8 million or 14.6% from the previous year’s comparable period.

15

Table of Contents

Net Revenue

Net revenue for the year ended December 31, 2007 increased $151.4 million, or 83%, to $333.7 million as compared to $182.3 million in 2006. Included in net revenue for the year ended December 31, 2007 was $39.4 million of recognized deferred revenue relating to the co-promotion agreement with AstraZeneca and the license agreement with Taiho as compared to $21.1 million for the year ended December 31, 2006.

Abraxane^® revenue for the year ended December 31, 2007 increased $149.8 million to $324.7 million as compared to $174.9 million in 2006. The increase was primarily due to product sales from increased market penetration and an increase of $18.2 million of recognized deferred revenue relating to the co-promotion agreement with AstraZeneca. Excluding the recognition of deferred revenue, total Abraxane^® revenue for the year ended December 31, 2007 increased 84.0% to $288.3 million from the prior year.

Other revenue increased to $9.0 million in 2007 as compared to $7.4 million in 2006, primarily because of $1.3 million of contract manufacturing revenue from the newly acquired Phoenix manufacturing facility.

Net revenue in 2006 increased $46.6 million, or 34.4%, to $182.3 million as compared to the prior year. Excluding $18.2 million of recognized deferred revenue relating to our co-promotion agreement with AstraZeneca in 2006, sales of Abraxane^® increased $23.0 million, or 17.2%, to $156.7 million compared to the prior year. The increase in Abraxane^® sales was primarily due to increased market penetration and the inclusion of a full year of sales in 2006 as compared to 2005 in which Abraxane^® launched in February.

Other revenue increased to $7.4 million in 2006, as compared to $1.9 million in 2005, primarily due to the achievement of a $3.0 million milestone payment received and recognition of $2.9 million in deferred revenue, resulting from the licensing agreement for Abraxane^® with Taiho. Net sales from our Switzerland operations were $1.2 million in 2006 as a result of the commencement of commercial production in 2006.

Net Revenue

Net revenue for the nine months ended September 30, 2007 increased $118.0 million, or 94%, to $242.9 million as compared to $124.9 million for the same period in 2006. Included in net revenue for the nine months ended September 30, 2007 was $29.4 million of recognized deferred revenue relating to the co-promotion agreement with AstraZeneca and the license agreement with Taiho as compared to $10.5 million for the nine months ended September 30, 2006.

Abraxane^® revenue for the nine months ended September 30, 2007 increased $117.2 million to $235.9 million as compared to $118.8 million in the same period of 2006. The increase was primarily due to product sales from increased market penetration and an increase of $18.2 million of recognized deferred revenue relating to the co-promotion agreement with AstraZeneca. Excluding the recognition of deferred revenue, total Abraxane^® revenue for the nine months ended September 30, 2007 increased to $208.6 million, or 90%, from the previous year’s comparable period.

17

Table of Contents

Net Revenue

Net revenue in 2006 increased $46.6 million, or 34.0%, to $182.3 million as compared to the prior year. Sales of Abraxane^® in 2006 increased $23.0 million, or 17.2%, to $156.7 million compared to the prior year, excluding $18.2 million of recognized deferred revenue relating to our co-promotion agreement with AstraZeneca. The increase in Abraxane^® sales was primarily due to increased market penetration and the inclusion of 12 full months of sales in 2006 as compared to 2005 in which Abraxane^® launched in February.

57

Table of Contents

Research revenue increased to $6.1 million in 2006, as compared to $1.9 million in 2005, primarily due to the achievement of a $3.0 million milestone payment received and recognition of $2.9 million in deferred revenue, resulting from the licensing agreement for Abraxane^® with Taiho. Net sales from our Switzerland operations were $1.2 million in 2006 as a result of the commencement of commercial production in 2006.

Net revenue in 2005 increased $135.4 million to $135.7 million as compared to the prior year. The increase was most entirely attributable to sales of Abraxane^® , which was launched in February 2005 and contributed $133.7 million in product sales to 2005 in the 11 months following launch. Research revenue increased to $1.9 million in 2005 from $0.2 million in 2004. The increase was primarily due to the recognition of $1.0 million in revenue under the Taiho license agreement for the marketing rights to Abraxane^® in Japan. Under this license agreement, Taiho paid us a non-refundable, upfront license payment of $20.0 million. However, due to the continuing involvement under the licensing agreement, recognition of the $20.0 million upfront payment was deferred and the payment is being recognized ratably over the estimated life of the product.